Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Janux Therapeutics
Biotech
Janux axes solid tumor T-cell engager after poor ph. 1 showing
The ‘overall magnitude and consistency of activity’ of JANX008 was subpar in its metastatic solid tumor trial.
Darren Incorvaia
Apr 28, 2026 4:15am
Astellas says 'I do' to Vir's T-cell engager in $1.7B deal
Feb 23, 2026 5:00pm
Cardiff Oncology churns C-suite—Chutes & Ladders
Jan 30, 2026 8:30am
BMS pens $850M tumor pact with T-cell engager biotech Janux
Jan 22, 2026 8:35am
Analyst deems Janux's stock spiral an 'overreaction'
Dec 2, 2025 11:14am
Takeda taps Julie Kim as new CEO—Chutes & Ladders
Jan 31, 2025 8:30am